Summary: Repeat video-EEG (VEEG) may increase diagnostic yield, but the test is resource intensive, time-consuming, and expensive and poses some potential risks to patients. It is also relatively common to monitor a patient for several days without capturing any clinical events. The purpose of this study was to determine the diagnostic value of repeat admissions for VEEG and to determine if the commonly available clinical information could predict the diagnostic outcome, "diagnostic" or "nondiagnostic," of a repeat study. A study was deemed diagnostic if the admission resulted in a definitive diagnosis of the patient's typical events. The authors retrospectively reviewed the charts of 3,727 patients completing scalp VEEG at the University of Alabama at Birmingham Epilepsy Center from 2002 to 2009. Minors, mentally retarded patients, and patients readmitted for surgical procedures or presurgical localization were excluded. Single and multiple regressions were used to determine if any of the parameters could predict the diagnostic outcome of a repeat VEEG study. Only younger age was independently predictive of a diagnostic readmission (P , 0.05), while longer total duration of monitoring was suggestive (P ¼ 0.07). A repeat VEEG study was useful in 55.2% of patients, most of whom were diagnosed after only 1 additional admission. In the patient population studied, 82.4% were diagnosed on the first admission (2,622 of 3,183), 52.9% on the second (46 of 87), and 40% on the third (2 of 5). Repeat VEEG admissions are useful, and clinical expertise may be the best tool for planning potential readmissions.
V ideo-EEG (VEEG) monitoring is widely used as a diagnostic tool in patients with a suspected seizure disorder. A definitive diagnosis by VEEG dictates treatment, decreases long-term societal expenses, and, in the case of a nonepileptic seizure diagnosis, reduces the risk and cost of unnecessary antiepileptic drug therapy (Alsaadi et al., 2004; Chemmanam et al., 2009; Martin et al., 1998) .
Video-EEG is a highly specific test but is not very sensitive: between 20% and 48% of patients admitted to the seizure monitoring unit had a nondiagnostic study and could potentially be readmitted for a repeat study (Ghougassian et al., 2004) . Repeat admission for VEEG may increase the number of definitive diagnoses, but the test is resource intensive, time-consuming, and expensive and poses some potential risk to patients (Ghougassian et al., 2004; Halpern et al., 2000; Lagerlund et al., 1996; Sanders et al., 1996) . The average charge for a VEEG study is several thousand dollars per day of monitoring (Halpern et al., 2000) . This is a substantial expense considering that most inpatient VEEG studies require several days of monitoring. The physical risks to a patient are primarily because of the necessary decrease in antiepileptic drugs and include uncontrolled behavior (ictal and postictal aggression, self-injurious behavior, and psychosis), seizure-related injuries (falls and status epilepticus), and the risk of pulling out surgically implanted electrodes (Sanders et al., 1996) . It is therefore imperative to elucidate which patients are good candidates for readmission to best use limited resources and reduce risk to the patient. The primary aim of this study was to determine the diagnostic value of repeat admissions for VEEG and to determine if the commonly available clinical information could predict the diagnostic outcome of a repeat study.
METHODS

Setting
The University of Alabama at Birmingham (UAB) Epilepsy Center is a regional tertiary center. The UAB seizure monitoring unit consists of 8 beds for intensive 24-hour continuous VEEG monitoring. Patients are admitted for either diagnostic purposes (e.g., to differentiate epileptic vs. nonepileptic seizures or for the classification and localization of the epilepsy syndrome) or as part of a presurgical workup for patients considering epilepsy surgery. Patients admitted for inpatient VEEG are referred by their neurologist or primary care physician for the following typical indications: (1) the patient has seizure-like events that need to be distinguished as epileptic or nonepileptic, (2) the patient has intractable seizures or has had an increase in events while on antiepileptic drugs, or (3) the patient is being evaluated for surgical candidacy for medically refractory epilepsy.
Patients
All patients completing scalp VEEG monitoring at the UAB Epilepsy Center from 2002 to 2009 were screened (N ¼ 3,727). Minors, mentally retarded patients, and patients readmitted for surgical procedures or presurgical localization were excluded. Of the remaining 3,183 patients, any patient with a nondiagnostic VEEG and at least 1 repeat admission was included in this study. A VEEG admission was deemed nondiagnostic if none of the patient's typical events were captured during the admission. Eighty-seven patients fulfilled these criteria. The following data were extracted: number of admissions, suspected seizure type, preadmission seizure frequency, length of stay, age, sex, race, final diagnosis, and the presence of epileptiform discharges during the nondiagnostic study. Provocative measures, including photic stimulation, hyperventilation, and sleep deprivation, are standardized in the UAB seizure monitoring unit and, except in rare cases where they are contraindicated, are applied equally for all patients. This study was approved by the Institutional Review Board of the University of Alabama at Birmingham and conducted in accordance with its guidelines.
Statistical Analyses
All analyses were performed using SPSS for Windows (SPSS, Inc, Chicago, IL). Data were expressed as means, standard deviations, proportions, and percentages. Chi-square differences in proportions and t-tests were used to assess group differences. Single and multiple regressions were used to determine if any of the parameters could predict the diagnostic outcome of a repeat VEEG study. A repeat VEEG study was deemed "diagnostic" if the admission resulted in a definitive diagnosis of the patient's typical events. A P value of ,0.05 was considered significant.
RESULTS
Descriptive Data
In total, 3,183 patients screened met exclusion criteria with 87 patients (2.7%) readmitted after a previous nondiagnostic VEEG monitoring admission. The descriptive data for these patients are summarized in Table 1 . Just over half of these (48; 55.2%) were diagnosed in a subsequent admission, and the rest (39; 44.8%) remained undiagnosed. The mean age for those diagnosed was 37 years (SD ¼ 12.5 years, range, 18 to 63 years), and those not diagnosed had a mean age of 41.7 years (SD ¼ 12.7 years, range, 19 to 78 years). There was no notable difference in race, sex, suspected seizure type, seizure frequency, or the presence of epileptiform discharges during the nondiagnostic study between diagnosed and undiagnosed patients. The VEEG results for the patients in this study are quantitatively shown in Table 2 . Of the 55.2% of patients who were eventually diagnosed, nearly all were diagnosed on the first readmission. In the total patient population studied, 82.4% were diagnosed on the first admission (2,622 of 3,183), 52.9% on the second (46 of 87), and 40% on the third (2 of 5).
Statistical Analysis
Only age was independently predictive of a diagnostic readmission (P , 0.05), with younger patients more likely to be diagnosed. A longer total duration of monitoring was somewhat predictive of an eventual diagnosis on readmission (P ¼ 0.07). The number of admissions, sex, race, suspected seizure type, the presence of epileptiform discharges during the nondiagnostic study, and seizure frequency were not predictive of a diagnostic readmission.
DISCUSSION
With regard to preadmission prediction of the outcome of a repeat VEEG study, most of the clinical parameters studied were not found to be predictive. Only one parameter, younger age, was found to be independently predictive. This finding is of questionable clinical significance because the difference in mean age between those diagnosed and not diagnosed was relatively small (37 and 41.7 years old, respectively). Reported baseline seizure frequency was not predictive because patients' assessments of average seizure frequency at home did not accurately reflect seizure frequency in the monitoring unit. It is reasonable to expect that a patient with a higher seizure frequency at home would be more likely to have a typical event on readmission, but this was not the case. The unreliability of patient-reported seizure counts has been previously demonstrated (Hoppe et al., 2007) . Furthermore, RuggeGunn et al. (2001) have quantitatively showed that the description of events by witnesses can be inaccurate and misleading and can lead to errors in diagnosis and subsequent treatment.
It is important to note that the diagnostic value of VEEG on readmission in this study might reflect the medical discretion of the referring physicians and their patient selection criteria. One example of how patient selection can affect diagnostic outcome can be seen by comparing the results presented herein with those of a very similar recently published study (Muniz and Benbadis, 2010) . The study by Muniz and Benbadis (2010) found that repeat VEEG admissions were useful in 81% of patients, whereas this study found repeat admissions to be useful in 55.2% of patients. One explanation for this discrepancy is the differing patient populations selected for readmission. Thirty-three percent of the patients readmitted in the study by Muniz and Benbadis (2010) had epileptiform discharges during the first admission but no recorded seizures. This was true for only 5.7% of patients readmitted in the present study. It seems likely that patients with interictal epileptiform discharges during the first admission would be more likely to have a seizure on a subsequent admission. The considerably larger proportion of such patients in the study by Muniz and Benbadis (2010) could explain the higher apparent utility of repeat VEEG in their study. Only a small percentage of patients with a nondiagnostic study were readmitted to the UAB Epilepsy Center (87 of 561; 15.5%). It is quite likely that the referring physicians readmitted these patients because clinical judgment dictated that the patients were likely to have a typical event on subsequent monitoring. However, this cannot be known for sure without a controlled study in which patients not selected for readmission are evaluated as well. This bias in our study certainly leads to an overestimation of the value of repeat VEEG.
This study showed that when clinical judgment dictated a readmission for VEEG, 55.2% of patients were definitively diagnosed, nearly all of whom were diagnosed on the first readmission. Even though VEEG is costly, a definitive diagnosis means a considerable saving in overall health care utilization. In a previous study at our center, when patients were diagnosed with nonepileptic seizures, there was an average of 84% reduction in future medical expenses (Martin et al., 1998) . A patient with a diagnosis of epilepsy would also presumably see a decrease in expenditures because of more optimized control of seizures with subsequently fewer emergency room visits, hospital admissions, epilepsy-related injuries, specialist consultations, and adverse drug reactionsdalthough these costs remain relatively unquantified.
Ultimately, at least 20% of patients admitted for VEEG had nondiagnostic studies. The cost of readmitting these patients must be weighed against the potential savings and improved health offered by a definitive diagnosis. Clinical judgment and expertise appear to be the best means for planning potential readmission.
